Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: First reported case
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessAttribution 4.0 Internationalhttps://creativecommons.org/licenses/by/4.0/Tarih
2023Yazar
Mutlu, Yaşa GülYiğit Kaya, Süreyya
Maral, Senem
Melek, Elif
Başlar, Zafer
Kaynar, Leylagül
Sevindik, Ömür Gökmen
Üst veri
Tüm öğe kaydını gösterKünye
Mutlu, Y. G., Yiğit Kaya, S., Maral, S., Melek, E., Başlar, Z., Kaynar, L. ... Sevindik, Ö. G. (2023). Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: First reported case. Frontiers in Immunology, 14. https://dx.doi.org/10.3389/fimmu.2023.1276295Özet
Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication associated with poor prognosis and limited treatment options. Emerging T-cell directing therapies, such as bispecific antibodies (bsAbs) and chimeric antigen receptor T cells (CAR-T), have shown remarkable success in treating MM, but their efficacy in CNS involvement remains unclear. Elranatamab, a humanized bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3-expressing T cells, has demonstrated promising results in relapsed refractory MM. However, its efficacy in treating CNS-MM has not been reported. We present a case of a 37-year-old male MM patient with CNS involvement who has been successfully treated with Elranatamab.
WoS Q Kategorisi
Q1Scopus Q Kategorisi
Q1Kaynak
Frontiers in ImmunologyCilt
14Koleksiyonlar
- Makale Koleksiyonu [3694]
- PubMed İndeksli Yayınlar Koleksiyonu [4109]
- Scopus İndeksli Yayınlar Koleksiyonu [6389]
- WoS İndeksli Yayınlar Koleksiyonu [6510]